Search Results - "SANTOS, Fabio P. S"

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis by Santos, Fabio P. S., Getta, Bartlomiej, Masarova, Lucia, Famulare, Christopher, Schulman, Jessica, Datoguia, Tarcila S., Puga, Renato D., Alves Paiva, Raquel de Melo, Arcila, Maria E., Hamerschlak, Nelson, Kantarjian, Hagop M., Levine, Ross L., Campregher, Paulo Vidal, Rampal, Raajit K., Verstovsek, Srdan

“…RAS -pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS -pathway mutations in patients…”
Get full text

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations by Jabbour, Elias, Cortes, Jorge, Santos, Fabio P.S., Jones, Dan, O'Brien, Susan, Rondon, Gabriela, Popat, Uday, Giralt, Sergio, Kebriaei, Partow, Jones, Roy B., Kantarjian, Hagop, Champlin, Richard, de Lima, Marcos

“…Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for…”
Get full text

Therapy with azanucleosides for myelodysplastic syndromes by Quintás-Cardama, Alfonso, Santos, Fabio P. S, Garcia-Manero, Guillermo

“…The use of azanucleosides has altered the treatment paradigm of myelodysplastic syndromes. Recently, treatment with 5-azacitidine was demonstrated to prolong…”
Get full text

JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? by Santos, Fabio P S, Verstovsek, Srdan

“…An activating mutation (V617F) in the pseudokinase domain of the Janus kinase (JAK)-2 tyrosine kinase has been described in 90% of patients with polycythemia…”
Get more information

Efficacy of ruxolitinib for myelofibrosis by Santos, Fabio P S, Verstovsek, Srdan

“…The discovery of the activating JAK2 V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to…”
Get more information

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis by Santos, Fabio P.S., Kantarjian, Hagop M., Jain, Nitin, Manshouri, Taghi, Thomas, Deborah A., Garcia-Manero, Guillermo, Kennedy, Debra, Estrov, Zeev, Cortes, Jorge, Verstovsek, Srdan

“…Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine…”
Get full text

Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia by Santos, Fabio P. S., Kantarjian, Hagop, Fava, Carmen, O’Brien, Susan, Garcia‐Manero, Guillermo, Ravandi, Farhad, Wierda, William, Thomas, Deborah, Shan, Jianquin, Cortes, Jorge

“…Summary Second (2nd)‐generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) are effective in patients with all phases of chronic myeloid leukaemia…”
Get full text

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy by Ravandi, Farhad, Cortes, Jorge, Faderl, Stefan, O'Brien, Susan, Garcia-Manero, Guillermo, Verstovsek, Srdan, Santos, Fabio P.S., Shan, Jianqin, Brandt, Mark, de Lima, Marcos, Pierce, Sherry, Kantarjian, Hagop

“…Pretreatment characteristics and outcome of patients treated with induction regimens containing high-dose ara-C (HiDAC) at M. D. Anderson Cancer Center…”
Get full text

JAK2 inhibitors: What's the true therapeutic potential? by Santos, Fabio P.S, Verstovsek, Srdan

“…Abstract Physicians treating patients with the classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) (polycythemia vera [PV], essential…”
Get full text

Molecular Characterization of a First-in-Human Clinical Response to Nimesulide in Acute Myeloid Leukemia by Tomaz, Victória, Griesi-Oliveira, Karina, Puga, Renato D., Conti, Bruno J., Santos, Fabio P. S., Hamerschlak, Nelson, Campregher, Paulo V.

“…Acute myeloid leukemia (AML) is a hematologic malignancy associated with high morbidity and mortality. Here we describe a case of a patient with AML who…”
Get full text

Evolution of therapies for chronic myelogenous leukemia by Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge

“…The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development…”
Get full text

Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib by Santos, Fabio P. S., Alvarado, Yesid, Kantarjian, Hagop, Verma, Dushyant, O'Brien, Susan, Mattiuzzi, Gloria, Ravandi, Farhad, Borthakur, Gautam, Cortes, Jorge

“…BACKGROUND: Anemia is a frequent side effect of imatinib in patients with chronic myeloid leukemia (CML). Erythropoietic‐stimulating agents have been used for…”
Get full text

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes by Bernard, Elsa, Nannya, Yasuhito, Hasserjian, Robert P., Devlin, Sean M., Tuechler, Heinz, Medina-Martinez, Juan S., Yoshizato, Tetsuichi, Shiozawa, Yusuke, Saiki, Ryunosuke, Malcovati, Luca, Levine, Max F., Arango, Juan E., Zhou, Yangyu, Solé, Francesc, Cargo, Catherine A., Haase, Detlef, Creignou, Maria, Germing, Ulrich, Zhang, Yanming, Gundem, Gunes, Sarian, Araxe, van de Loosdrecht, Arjan A., Jädersten, Martin, Tobiasson, Magnus, Kosmider, Olivier, Follo, Matilde Y., Thol, Felicitas, Pinheiro, Ronald F., Santini, Valeria, Kotsianidis, Ioannis, Boultwood, Jacqueline, Santos, Fabio P. S., Schanz, Julie, Kasahara, Senji, Ishikawa, Takayuki, Tsurumi, Hisashi, Takaori-Kondo, Akifumi, Kiguchi, Toru, Polprasert, Chantana, Bennett, John M., Klimek, Virginia M., Savona, Michael R., Belickova, Monika, Ganster, Christina, Palomo, Laura, Sanz, Guillermo, Ades, Lionel, Della Porta, Matteo Giovanni, Elias, Harold K., Smith, Alexandra G., Werner, Yesenia, Patel, Minal, Viale, Agnès, Vanness, Katelynd, Neuberg, Donna S., Stevenson, Kristen E., Menghrajani, Kamal, Bolton, Kelly L., Fenaux, Pierre, Pellagatti, Andrea, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Chiba, Shigeru, Miyazaki, Yasushi, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Fontenay, Michaela, Jansen, Joop H., Cervera, José, Atsuta, Yoshiko, Gattermann, Norbert, Ebert, Benjamin L., Bejar, Rafael, Greenberg, Peter L., Cazzola, Mario, Hellström-Lindberg, Eva, Ogawa, Seishi, Papaemmanuil, Elli

“…Tumor protein p53 ( TP53 ) is the most frequently mutated gene in cancer 1 , 2 . In patients with myelodysplastic syndromes (MDS), TP53 mutations are…”
Get full text

Acute Sickle Hepatic Crisis After Liver Transplantation in a Patient With Sickle β-Thalassemia by PERINI, Guilherme F, SANTOS, Fabio P. S, FERRAZ NETO, José Ben-Hur, PASQUALIN, Denise, HAMERSCHLAK, Nelson

Get full text

Decitabine in the treatment of myelodysplastic syndromes by Santos, Fabio PS, Kantarjian, Hagop, Garcia-Manero, Guillermo, Issa, Jean-Pierre, Ravandi, Farhad

“…Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral…”
Get full text

Acute erythroleukemia: diagnosis and management by Santos, Fabio P S, Bueso-Ramos, Carlos E, Ravandi, Farhad

“…Acute erythroleukemia is a rare subtype of acute myeloid leukemia that has undergone several changes in classification over the past 30 years. There are two…”
Get more information

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia by Santos, Fabio P. S., Jones, Dan, Qiao, Wei, Cortes, Jorge E., Ravandi, Farhad, Estey, Elihu E., Verma, Dushyant, Kantarjian, Hagop, Borthakur, Gautam

“…BACKGROUND: The impact of FMS‐like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia…”
Get full text

Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? by Santos, Fabio P S, O'Brien, Susan

“…Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, characterized by peripheral blood B-cell lymphocytosis as well as…”
Get full text

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes by Sirenko, Maria, Bernard, Elsa, Creignou, Maria, Domenico, Dylan, Farina, Andrea, Arango Ossa, Juan E., Kosmider, Olivier, Hasserjian, Robert, Jädersten, Martin, Germing, Ulrich, Sanz, Guillermo, van de Loosdrecht, Arjan A., Gurnari, Carmelo, Follo, Matilde Yung, Thol, Felicitas, Zamora, Lurdes, Pinheiro, Ronald Feitosa, Pellagatti, Andrea, Elias, Harold K., Haase, Detlef, Sander, Birgitta, Orna, Elisa, Zoldan, Katharina, Eder, Lea Naomi, Sperr, Wolfgang R., Thalhammer, Renate, Ganster, Christina, Adès, Lionel, Tobiasson, Magnus, Palomo, Laura, Della Porta, Matteo Giovanni, Huberman, Kety, Fenaux, Pierre, Belickova, Monika, Savona, Michael R., Klimek, Virginia M., Santos, Fabio P. S., Boultwood, Jacqueline, Kotsianidis, Ioannis, Santini, Valeria, Solé, Francesc, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Ogawa, Seishi, Fontenay, Michaela, Jansen, Joop H., Cervera, Jose, Ebert, Benjamin L., Bejar, Rafael, Greenberg, Peter L., Gattermann, Norbert, Malcovati, Luca, Cazzola, Mario, Beck, David B., Hellström-Lindberg, Eva, Papaemmanuil, Elli

“…•UBA1 mutations were identified in 1% of patients with MDS and 7% of patients lacking myeloid mutations or established disease classification.•Inflammatory…”
Get full text

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation by Santos, Fabio P. S., Tam, Constantine S., Kantarjian, Hagop, Cortes, Jorge, Thomas, Deborah, Pollock, Raphael, Verstovsek, Srdan

“…Abstract Splenectomy may be an effective therapeutic option for treating massive splenomegaly in patients with myeloproliferative neoplasms (MPNs). There are…”
Get full text